期刊
HEPATOLOGY INTERNATIONAL
卷 11, 期 4, 页码 317-370出版社
SPRINGER
DOI: 10.1007/s12072-017-9799-9
关键词
Hepatocellular carcinoma; Asia-Pacific; APASL; Treatment algorithm
资金
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Otsuka
- Astellas
- Gilead Sciences
- Chugai
- Mitsubishi Tanabe
- Kyorin
- Merck Sharp and Dohme
- Dainippon Sumitomo
- Vertex Pharmaceuticals
- Takeda
- Merck Serono
- Zeria
- Novartis
- Eisai
- ONXEO
- Ono Pharmaceutical
- Ajinomoto
- AbbVie
- Kowa
- Taiho
- Roche
- Grants-in-Aid for Scientific Research [16K10363] Funding Source: KAKEN
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据